Free tool
FAERS Monitor: Contrave
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200063 or its brand name (Contrave, Bupropion Hydrochloride, Naltrexone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
8,503
Serious
2,837
33% of reports
Hospitalization
562
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,989
- headache1,116
- dizziness1,051
- vomiting680
- constipation648
- feeling abnormal583
- fatigue526
- anxiety406
- insomnia396
- diarrhoea374
- drug ineffective368
- patient dissatisfaction with treatment344
- tremor337
- drug titration error333
- illness332
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 13 |
| 2015 | 1,572 |
| 2016 | 832 |
| 2017 | 210 |
| 2018 | 243 |
| 2019 | 308 |
| 2020 | 439 |
| 2021 | 276 |
| 2022 | 355 |
| 2023 | 432 |
| 2024 | 1,327 |
| 2025 | 2,412 |
| 2026 | 84 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,656 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| patient dissatisfaction with treatmentSignal | 344 | 537.2 | 479.0 | 150,845 |
| drug titration errorSignal | 333 | 366.1 | 327.0 | 105,331 |
| illnessSignal | 332 | 8.0 | 7.2 | 2,028 |
| constipationSignal | 648 | 7.4 | 6.8 | 3,587 |
| nauseaSignal | 1,989 | 6.2 | 6.0 | 9,045 |
| feeling abnormalSignal | 583 | 6.0 | 5.6 | 2,463 |
| dizzinessSignal | 1,051 | 5.2 | 4.9 | 3,662 |
| tremorSignal | 337 | 5.0 | 4.5 | 1,091 |
| headacheSignal | 1,116 | 4.4 | 4.2 | 3,023 |
| insomniaSignal | 396 | 3.7 | 3.3 | 780 |
| vomitingSignal | 680 | 3.6 | 3.3 | 1,290 |
| anxietySignal | 406 | 3.5 | 3.2 | 744 |
| fatigue | 526 | 1.7 | 1.5 | 147 |
| diarrhoea | 374 | 1.4 | 1.3 | 50 |
| drug ineffective | 368 | 0.7 | 0.6 | 54 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.